Pronunciation: BROME-fen-IR-a-meen MAL-ee-ate
Class: Antihistamine, Alkylamine, nonselective
- Liquid, oral 1 mg/mL
Competitively antagonizes histamine at H 1 receptor sites.
T max is approximately 5 h.
Major route of elimination is urinary excretion. Half-life is approximately 25 h.
Indications and Usage
Relief of sneezing; itchy, watery eyes; itchy nose or throat; and runny nose because of hay fever (allergic rhinitis) or other upper respiratory allergies.
None well documented.
Dosage and AdministrationChildren 6 to 12 y of age
PO 2 dropperfuls (2 mL) every 4 to 6 h, up to 12 dropperfuls (12 mL) in 24 h.Children 2 to younger than 6 y
PO 1 dropperful (1 mL) every 4 to 6 h, up to 6 dropperfuls (6 mL) in 24 h.
Store at 59° to 86°F.
Drug InteractionsAlcohol, CNS depressants (eg, sedatives, tranquilizers)
Effects may be enhanced by brompheniramine.Sodium oxybate
Coadministration may result in increased sleep duration and CNS depression. Coadministration is contraindicated.
Assess allergy symptoms (eg, cough; rhinitis; nasal congestion; sneezing; watery eyes; itchy nose, throat, or eyes) before starting therapy and periodically during therapy.
Category undetermined . Exposure near the birth of premature infants has been associated with an increased risk of retrolental fibroplasia.
Excreted in breast milk.
Per the Beers criteria, avoid use in elderly patients.
Special Risk Patients
Use with caution in patients with respiratory disorders (eg, chronic bronchitis) or glaucoma.
May cause drowsiness. Excitability may occur, especially in children.
No data available.
- Inform patients not to exceed the recommended dosage and to discontinue use and contact a health care provider if new symptoms occur.
- Inform patients that drowsiness may occur; excitability may also occur, especially in children.
- Advise patients to avoid activities that require mental alertness and motor coordination until they know how the medication affects them.
- Advise patients to avoid alcohol and that use with other CNS depressants may cause additive drowsiness.
- Advise patients to check with their health care provider prior to use if they have glaucoma or a respiratory disorder (eg, chronic bronchitis), or if they are pregnant or breast-feeding.
Copyright © 2009 Wolters Kluwer Health.
More Brompheniramine resources
- brompheniramine 12-hour sustained-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- brompheniramine Concise Consumer Information (Cerner Multum)
- Brompheniramine Maleate, Dexbrompheniramine Maleate Monograph (AHFS DI)
- Brovex suspension MedFacts Consumer Leaflet (Wolters Kluwer)
- Brovex CT chewable tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Lodrane 24 24-hour sustained-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- VaZol liquid MedFacts Consumer Leaflet (Wolters Kluwer)